达芦那韦血浆浓度偏低的风险因素分析
该回顾性研究纳入113例启动达芦那韦治疗HIV感染者,分析首次治疗8周内血浆浓度。二分类逻辑回归显示,除食物摄入外,年龄与估算肾小球滤过率是预测达芦那韦浓度低于群体药代动力学曲线中位数的最佳变量组合(Hosmer-Lemeshow检验P=0.945,Nagelkerke R2=0.284)。系统评估治疗药物监测结果有助于识别低药物暴露风险患者。
要点
- 年龄与eGFR是达芦那韦低浓度的预测因素。
- 食物摄入也影响达芦那韦血浆浓度。
- 系统评估TDM可识别低暴露风险患者。
核心结论
- 年龄联合估算肾小球滤过率可预测达芦那韦浓度低于群体药代动力学曲线中位数。
研究设计与样本
- 选取启动达芦那韦治疗8周内的首次血浆浓度,采用二分类逻辑回归分析。
主要发现
- 除食物摄入外,年龄与估算肾小球滤过率是预测达芦那韦低浓度的最佳变量组合(Hosmer-Lemeshow检验P=0.945,Nagelkerke R2=0.284)。
临床怎么用
- 系统评估治疗药物监测结果可能有助于识别达芦那韦低药物暴露风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once- or twice-daily dosage. Darunavir plasma concentrations from January 2010 till December 2014 of human immunodeficiency virus-infected individuals treated in the outpatient clinic of the University Medical Center Groningen were retrospectively reviewed. The first darunavir plasma concentration of patients within 8 weeks after initiation of darunavir therapy was selected. A dichotomous logistic regression analysis was conducted to select the set of variables best predicting a darunavir concentration below median population pharmacokinetic curve. In total 113 patients were included. The variables best predicting a darunavir concentration besides food intake included age together with estimated glomerular filtration rate (Hosmer-Lemeshow test P = 0.945, Nagelkerke R2 = 0.284). Systematic evaluation of therapeutic drug monitoring results may help to identify patients at risk for low drug exposure.
引用
- Daskapan A, Stienstra Y, Kosterink JGW, et al. Risk factors contributing to a low darunavir plasma concentration. Br J Clin Pharmacol. 2017. PMID: 29077230. doi:10.1111/bcp.13464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。